An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-fine HIV therapy is optimal in resource-limited settings： a prospective, multicenter study in China
An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-fine HIV therapy is optimal in resource-limited settings： a prospective, multicenter study in China作者机构：Department of Infectious Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing 100730China The infectious Disease Hospital of Henan Province ZhengzhouHenan 450061 China Shanghai Public Health Clinical Center Fudan University Shanghai201508 China Fuzhou Infectious Diseases Hospital Fujian Medical UniversityFuzhou Fujian 350002 China Guangzhou No. 8 People's Hospital Guangzhou Guangdong 510060 China Shenzhen Third People's Hospital Shenzhen Guangdong 518112China Beijing You'an Hospital Capital Medical University Beijing 100054China Beijing Ditan Hospital Capital Medical University Beijing 100011China Yunnan AIDS Care Center Kunming Yunnan 650000 China The First People's Hospital of Honghe State Honghe Yunnan 650000 China Tangdu Hospital Affiliated to the Fourth Military Medical UniversityXi'an Shaanxi 710038 China Kunming Third People's Hospital Kunming Yunnan 650041 China
出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)
年 卷 期：2014年第127卷第1期
页 面：59-65页
核心收录：
学科分类：0710[理学-生物学] 12[管理学] 1201[管理学-管理科学与工程(可授管理学、工学学位)] 07[理学] 08[工学] 09[农学] 071007[理学-遗传学] 070105[理学-运筹学与控制论] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 0701[理学-数学]
基 金：supported by the National Key Technologies R&D Program for the 11th Five-Year Plan the 12th Five-Year Plan Key Clinical Program of the Ministry of Health
主 题：human immunodeficiency virus acquired immunodeficiency syndrome antiretroviral therapy zidovudine stavudine anemia lipodystrophy
摘 要：Background An zidovudine （AZT）-substitution regimen containing 24-week stavudine （d4T） followed by long-term AZT for HIV therapy is potential to trade off short-term AZT-related anemia and long-term risks associated with d4T in resourcelimited ***,evidence is *** study aims to assess the efficacy and safety of AZT-substitution regimen,aiming to find a regimen with better efficacy,less adverse events,and more affordability in resource-limited *** This prospective,multicenter study enrolled 499 （190 on d4T regimen,172 on AZT regimen,and 137 on AZT-substitution regimen） HIV-1-infected subjects who initiated combined antiretroviral therapy and attended follow-up visits over 96 weeks from 2009 to *** （3TC） and either nevirapine （NVP） or efavirenz （EFV） were the other two drugs in the antiretroviral *** and immunologic responses and adverse events were monitored at baseline and at weeks 4,12,24,36,48,60,72,84,and *** In terms of hematological adverse effects,AZT-substitution group had similar safety profiles to d4T group and was superior to AZT *** comparison with AZT-substitution group,AZT group was associated with higher risk of developing anemia （adjusted hazard ratio （aHR）for anemia ≥ grade Ⅱ,8.44,95％ CI 1.81-39.46） and neutropenia （aHR for neutropenia ≥ grade Ⅱ,1.86,95％ CI 1.19-2.93）.The prevalence of lipodystrophy in d4T group was 19.5％,while that in AZT-substitution group was *** to antiretroviral efficacy,these three groups showed no *** AZT-substitution regimen provides a relatively safe and effective first-line antiretroviral strategy in resource-limited settings.
维普期刊数据库